Filters
The PARP* inhibitor niraparib improves progression-free survival (PFS) and is well-tolerated in women with newly diagnosed advanced ovarian cancer (OCa) after a response to first-line (1L) platinum-based chemotherapy (CT), subgroup results of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial have shown.
The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.
The combination of gemcitabine plus albumin-bound paclitaxel (ABP) appears to be well tolerated and effective in the first-line treatment of patients with advanced squamous cell lung cancer (SQCLC), according to the results of a phase II study.
Two phase III trials reflect the sustained efficacy and safety of the bDMARD* ixekizumab in bDMARD-naïve (COAST-V) or TNFi**-experienced (COAST-W) adults with active radiographic axial spondyloarthritis (r-axSpA), also known as ankylosing spondylitis (AS).
The novel rifabutin-based triple therapy (RHB-105) delivers promising outcomes as first-line empirical treatment for Helicobacter pylori eradication, according to the results of a phase III, double blind trial. This therapy addresses the challenge of rising antibiotic resistance in the current environment.
Patients with axial and peripheral psoriatic arthritis (PsA) who switch to a second or third tumour necrosis factor inhibitor (TNFi) have significantly lower drug survival and response rates, a recent study has found.
The immune checkpoint inhibitor nivolumab yields long-term overall survival (OS) gains in treatment-experienced patients with gastric/gastroesophageal junction (G/GEJ), with the benefit most pronounced among those who show a complete (CR) or partial response (PR), according to the 2-year follow-up results of the phase III ATTRACTION-2a study.
Singapore’s Ministry of Health (MOH) has confirmed 876 new cases of COVID-19 infection on May 10. Two casualties have been recorded on May 6, bringing the total COVID-19 deaths in the city-state to 20. Older age seems a common factor among them.
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Adults who develop peanut allergy in adulthood are less likely to receive a physician diagnosis of their allergy or use epinephrine compared with those with childhood-onset peanut allergy, according to a study from the US.
